GORE VIATORR TIPS Endoprosthesis with Controlled Expansion
W. L. Gore & Associates, Inc. · Decision date Oct 27, 2025
What did the FDA approve?
FDA records P040027/S099 as a supplement to PMA P040027, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 27, 2025.
FDA approval order statement
approval for a modification to the controlled expansion sleeve that allows the device to have a 6-10 mm adjustable diameter range (as opposed to the existing 8-10 mm diameter range)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 27, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P040027/S099
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MIR
- Decision code
- APPR
- Decision date
- Oct 27, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MIR
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040027/S099 received
Application receipt date recorded by FDA.
P040027/S099 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P040027. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MIR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Liverty TIPS Stent GraftP250050/S001 | Bard Peripheral Vascular, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Liverty TIPS Stent GraftP250050 | Bard Peripheral Vascular, Inc. | PMA approval | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 32360 N. N. Valley Pkwy., Phonix, AZ, 85085
Sources and methodology
- Original FDA record: P040027/S099
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
